Sprint Bioscience AB (DE:5JA1)

FRANKFURT:5JA1

5JA1

Sprint Bioscience AB

RESEARCH TOOLSreports

Want to see DE:5JA1 full AI Analyst Report?

Sprint Bioscience AB (5JA1) Price & Analysis

0 Followers

5JA1 Stock Chart & Stats

€0.11

>-€0.01(-2.52%)

At close: Jan 08 4:00 PM EST

€0.11

>-€0.01(-2.52%)

Day’s Range― - ―

52-Week Range€0.02 - €0.35

Previous CloseN/A

Volume0.00

Average Volume (3M)83.00

Market Cap

€33.23M

Enterprise Value€270.47M

Total Cash (Recent Filing)€126.70M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta2.08

Next Earnings

Aug 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.83

Shares Outstanding105,515,540

10 Day Avg. Volume250

30 Day Avg. Volume83

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)1.14

Price to Sales (P/S)0.81

P/FCF Ratio1.63

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)€7.44M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetZero reported debt across 2021–2025 materially reduces refinancing and interest-rate risk, giving management durable optionality to fund R&D or wait for higher-value licensing outcomes. A debt-free position supports longer runway and strategic flexibility in biotech partnerships.

2025 Profitability InflectionA clear 2025 step-change to positive net income and improved gross profit suggests the business can convert partnership or milestone receipts into durable operating leverage. If sustained, this demonstrates the model can generate self-funding cash flow for continued discovery investment.

Proprietary Discovery & Partner-focused ModelOwning a proprietary small-molecule discovery platform and a partner-out-licensing business model aligns Sprint to capture early value from programs while limiting late-stage clinical risk. This asset + execution model is structurally suited to steady deal-driven value realization in oncology discovery.

Bears Say

Volatile Earnings And Cash FlowsHistorical swings from losses to strong profits and uneven operating cash flows reduce forecasting reliability and make budgeting R&D and operations harder. Persistent volatility can force dilutive fundraising or opportunistic deal timing despite recent profitable periods.

Revenue Lumpiness From Partnership TimingDependence on discrete upfronts, milestones and royalties means revenue recognition timing drives performance more than recurring sales. Structurally lumpy receipts complicate steady cash generation, increasing working-capital variability and planning risk for multi-year discovery investments.

Small Scale And Funding SensitivityA small organization with a previously very low equity base indicates sensitivity to funding cycles and cash burn. Even with current profits and no debt, the company remains vulnerable to the timing of partner deals and may need capital raises that dilute shareholders or alter strategy if deal flow softens.

5JA1 FAQ

What was Sprint Bioscience AB’s price range in the past 12 months?

Sprint Bioscience AB lowest stock price was €0.02 and its highest was €0.35 in the past 12 months.

What is Sprint Bioscience AB’s market cap?

Sprint Bioscience AB’s market cap is €33.23M.

When is Sprint Bioscience AB’s upcoming earnings report date?

Sprint Bioscience AB’s upcoming earnings report date is Aug 26, 2026 which is in 96 days.

How were Sprint Bioscience AB’s earnings last quarter?

Sprint Bioscience AB released its earnings results on May 13, 2026. The company reported -€0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.011.

Is Sprint Bioscience AB overvalued?

According to Wall Street analysts Sprint Bioscience AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sprint Bioscience AB pay dividends?

Sprint Bioscience AB does not currently pay dividends.

What is Sprint Bioscience AB’s EPS estimate?

Sprint Bioscience AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sprint Bioscience AB have?

Sprint Bioscience AB has 105,515,540 shares outstanding.

What happened to Sprint Bioscience AB’s price movement after its last earnings report?

Sprint Bioscience AB reported an EPS of -€0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.625%.

Which hedge fund is a major shareholder of Sprint Bioscience AB?

Currently, no hedge funds are holding shares in DE:5JA1

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sprint Bioscience AB

Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was founded in 2009 and is based in Huddinge, Sweden.